We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III
Read MoreHide Full Article
AstraZeneca Plc (AZN - Free Report) announced positive top-line results from a phase III study evaluating its investigational triple combination therapy PT010 for the treatment of chronic obstructive pulmonary disease (COPD).
PT010 is a combination of budesonide, an ICS with glycopyrronium, a long-acting muscarinic antagonist (LAMA) and formoterol fumarate, a LABA therapy.
PT010 is being developed by delivering AstraZeneca’s Aerosphere Delivery Technology.
The KRONOS study compared PT010 to dual combination therapies — Bevespi Aerosphere, (Symbicort Turbuhaler, and PT009). The company will present the KRONOS trial results at a forthcoming medical meeting.
The study demonstrated PT010’s efficacy in improving lung function. The study showed significant improvement compared with dual combination therapies in six out of nine lung function primary endpoints. The study was based on forced expiratory volume in one second (FEV1) assessments in patients with moderate to very severe COPD.
Shares of AstraZeneca have gained 35.2% over a year while the industry registered an increase of 29%.
AstraZeneca expects to make regulatory submissions in Japan and China in the second half of 2018, followed by potential submissions in the United States and Europe in 2019.
We remind investors that last year the FDA approved, GlaxoSmithKline (GSK - Free Report) and partner Innoviva (INVA - Free Report) once-daily, single inhaler triple combination therapy Trelegy Ellipta, for the treatment of COPD.
Trelegy Ellipta is a combination of fluticasone furoate – an ICS, umeclidinium – a long-acting muscarinic antagonist (LAMA) and vilanterol – a LABA therapy. Trelegy Ellipta will be delivered in Glaxo’ Ellipta dry powder inhaler.
AbbVie’s earnings per share estimates have moved up from $6.55 to $6.58 for 2018 in the last 60 days. The company delivered a positive earnings surprise in the last four quarters, the average being 1.81%. Share price of the company surged 103.9% over a year.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III
AstraZeneca Plc (AZN - Free Report) announced positive top-line results from a phase III study evaluating its investigational triple combination therapy PT010 for the treatment of chronic obstructive pulmonary disease (COPD).
PT010 is a combination of budesonide, an ICS with glycopyrronium, a long-acting muscarinic antagonist (LAMA) and formoterol fumarate, a LABA therapy.
PT010 is being developed by delivering AstraZeneca’s Aerosphere Delivery Technology.
The KRONOS study compared PT010 to dual combination therapies — Bevespi Aerosphere, (Symbicort Turbuhaler, and PT009). The company will present the KRONOS trial results at a forthcoming medical meeting.
The study demonstrated PT010’s efficacy in improving lung function. The study showed significant improvement compared with dual combination therapies in six out of nine lung function primary endpoints. The study was based on forced expiratory volume in one second (FEV1) assessments in patients with moderate to very severe COPD.
Shares of AstraZeneca have gained 35.2% over a year while the industry registered an increase of 29%.
AstraZeneca expects to make regulatory submissions in Japan and China in the second half of 2018, followed by potential submissions in the United States and Europe in 2019.
We remind investors that last year the FDA approved, GlaxoSmithKline (GSK - Free Report) and partner Innoviva (INVA - Free Report) once-daily, single inhaler triple combination therapy Trelegy Ellipta, for the treatment of COPD.
Trelegy Ellipta is a combination of fluticasone furoate – an ICS, umeclidinium – a long-acting muscarinic antagonist (LAMA) and vilanterol – a LABA therapy. Trelegy Ellipta will be delivered in Glaxo’ Ellipta dry powder inhaler.
Astrazeneca PLC Price
Astrazeneca PLC Price | Astrazeneca PLC Quote
Zacks Rank & Stock to Consider
AstraZeneca has a Zacks Rank #3 (Hold).
A better-ranked stock from the health care space is AbbVie Inc. (ABBV - Free Report) carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AbbVie’s earnings per share estimates have moved up from $6.55 to $6.58 for 2018 in the last 60 days. The company delivered a positive earnings surprise in the last four quarters, the average being 1.81%. Share price of the company surged 103.9% over a year.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>